Sanofi is voluntarily recalling all 2.8 million of its Auvi-Q epinephrine injectors from the U.S. and Canada.
The products have been found to potentially have inaccurate dosage delivery. The recall involves all Auvi-Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers, and consumers.
The injectors are used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for, or have a history of these reactions.
Mylan, which makes rival product, EpiPen, has quickly confirmed it has sufficient supply of its auto-injector to meet any anticipated demand.
Read the Sanofi press release
